article thumbnail

How big data analytics can make personalised care a reality

Drug Discovery World

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. This could be expanded to assessing predictors at baseline.

article thumbnail

Democratising proteomics for cancer and beyond

Drug Discovery World

At the beginning of 2023, proteomics company Nautilus Biotechnology announced a partnership with the Translational Genomics Research Institute (TGen), to study the specific proteins at work in the rare and often fatal childhood cancer, diffuse intrinsic pontine glioma (DIPG). BMC Bioinformatics. 2013;14 Suppl 2(Suppl 2):S24.

Protein 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What to expect from SLAS Europe 2023

Drug Discovery World

Additionally, Dr Gianni will share insights on the use of these new tools in target validation and how they might revolutionise the drug discovery paradigm.

Doctors 52
article thumbnail

FAIR Game: making data work harder in the race to market 

Drug Discovery World

For example, GEO, the gene expression omnibus database, has been collecting gene expression and functional genomics datasets and making them available to the public for more than 20 years. Many efforts have been made to standardise certain types of results.

article thumbnail

Synthetic biology tools advancing and accelerating drug discovery efforts

Drug Discovery World

Gene-to-antibody production begins with scientists entering antibody sequences as starting material, after which bioinformatics tools filter out potentially non-viable sequences. Then, using DNA synthesis capabilities, oligo pools encoding for specific domains of the antibody are generated as libraries and cloned into a vector.

DNA 98